VDAC2 and B-cell non-Hodgkin lymphoma: Elesclomol, a cuproptosis inducer, binds to VDAC2, maintaining its opening and altering mitochondrial membrane permeability, which increases mitochondrial metabolism and ROS production.[60, 61, 62] Doxorubicin is a traditional chemotherapy agent used to treat B-cell NHL.